GLP-1受体激动剂与SGLT2抑制剂对2型糖尿病下肢截肢结局的差异效应:全国性回顾性队列研究
该回顾性队列研究基于TriNetX电子健康记录网络,纳入2013年5月至2025年3月间新启用GLP-1受体激动剂或SGLT2抑制剂的2型糖尿病成人,经1:1倾向评分匹配后各180,740例。结果显示,GLP-1受体激动剂组相比SGLT2抑制剂组3年无大截肢生存率更高(99.69% vs 99.64%,P=0.001),且大截肢、小截肢、糖尿病足溃疡及死亡风险均更低。作者结论认为,GLP-1受体激动剂治疗与更高的无大截肢生存率相关,尤其在高危亚组。
要点
- 匹配后GLP-1RA组与SGLT2i组各180,740例,3年无大截肢生存率分别为99.69%与99.64%(P=0.001)。
- GLP-1RA组大截肢风险(HR 0.77,95%CI 0.66-0.90)、小截肢风险(HR 0.73,95%CI 0.63-0.84)均低于SGLT2i组。
- GLP-1RA组糖尿病足溃疡风险(HR 0.92,95%CI 0.87-0.96)及死亡风险(HR 0.66,95%CI 0.63-0.69)均低于SGLT2i组。
核心结论
- 在2型糖尿病患者中,与SGLT2抑制剂相比,GLP-1受体激动剂治疗与更高的无大截肢生存率相关,尤其在高危亚组中。
- 作者指出,需要前瞻性研究来证实这些发现,并为有糖尿病相关截肢风险的人群选择降糖治疗提供依据。
研究设计与样本
- 本研究为回顾性队列研究,使用TriNetX联邦电子健康记录网络数据。
- 纳入2013年5月至2025年3月间新启用GLP-1受体激动剂或SGLT2抑制剂的2型糖尿病成人。
- 采用1:1倾向评分匹配平衡人口学特征、合并症、用药及实验室值,匹配后GLP-1RA组和SGLT2i组各180,740例。
- 采用Kaplan-Meier曲线评估无大截肢(踝以上)生存率,采用风险比(HR)及95%CI估计大截肢、小截肢、糖尿病足溃疡及死亡风险。
主要发现
- 3年时,GLP-1RA组无大截肢生存率为99.69%,SGLT2i组为99.64%(P=0.001)。
- GLP-1RA组相比SGLT2i组,大截肢风险HR为0.77(95%CI 0.66-0.90),小截肢风险HR为0.73(95%CI 0.63-0.84)。
- GLP-1RA组相比SGLT2i组,糖尿病足溃疡风险HR为0.92(95%CI 0.87-0.96),死亡风险HR为0.66(95%CI 0.63-0.69)。
- 在外周动脉疾病患者中,GLP-1RA组相比SGLT2i组大截肢风险HR为0.68(95%CI 0.56-0.82)。
- 在糖尿病足溃疡患者中,GLP-1RA组相比SGLT2i组大截肢风险HR为0.70(95%CI 0.58-0.84)。
临床怎么用
- 作者认为,GLP-1受体激动剂治疗与2型糖尿病患者更高的无大截肢生存率相关,尤其在高危亚组中。
- 作者指出,需要前瞻性研究来证实这些发现,并为有糖尿病相关截肢风险的人群选择降糖治疗提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of lower-extremity amputations (LEAs) between new users of glucagon-like peptide 1 receptor agonists (GLP-1RAs) versus sodium-glucose cotransporter 2 inhibitors (SGLT2is). RESEARCH DESIGN AND METHODS: This retrospective cohort study used TriNetX, a federated electronic health records network, including adults with type 2 diabetes who initiated GLP-1RAs or SGLT2is between May 2013 and March 2025. Propensity score matching (1:1) was used to balance demographics, comorbidities, medications, and laboratory values. Major (above-ankle) amputation-free survival was evaluated using Kaplan-Meier curves, while risks of major and minor LEAs, diabetic foot ulcers (DFUs), and mortality were estimated using hazard ratios (HRs) with 95% CIs. RESULTS: The matched cohorts included 180,740 GLP-1RA and 180,740 SGLT2i recipients. At 3 years, the GLP-1RA cohort was associated with greater major amputation-free survival (99.69% vs. 99.64%, P = 0.001) compared with the SGLT2i cohort. Additionally, GLP-1RA treatment was associated with a lower risk of major LEAs (HR 0.77 [95% CI 0.66, 0.90]), minor LEAs (HR 0.73 [95% CI 0.63, 0.84]), DFUs (HR 0.92 [95% CI 0.87, 0.96]), and mortality (HR 0.66 [95% CI 0.63, 0.69]). Risk reduction for major LEAs remained significant in individuals with peripheral artery disease (HR 0.68 [95% CI 0.56, 0.82]) and DFUs (HR 0.70 [95% CI 0.58, 0.84]). CONCLUSIONS: GLP-1RA treatment was associated with greater major amputation-free survival compared with SGLT2i in people with type 2 diabetes, particularly in high-risk subgroups. Prospective studies are needed to confirm findings and inform selection of glucose-lowering therapies for people at risk for diabetes-related amputations.
引用
- Hong AT, Luu IY, Lin F, et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care. 2025. PMID: 40560644. doi:10.2337/dc25-0292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。